大腸がんの世界市場の評価：治療タイプ別、診断別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

世界の大腸がんの市場規模は、2023年に150億6,000万米ドル、2031年に207億2,000万米ドルに達し、2024年～2031年の予測期間にCAGRで4.07%の成長が見込まれています。大腸がん治療・診断市場は、大腸がんの有病率の増加、医療技術の進歩、意識の高まりなどの要因が重なり、近年大幅な成長を示しています。WHOによると、大腸がんは3番目に多いがんで、がん全体の約10％を占めています。大腸がんの分野における研究開発の増加は、新製品や先進の製品を通じて市場を牽引しています。さらに、新薬の強力なパイプラインとがん撲滅に向けた政府の取り組みが、世界の大腸がん市場を牽引すると予測されています。大腸がんの有病率の急増は、遺伝子変異、炎症性腸疾患、ホルモンやライフスタイルの変化、アルコールやタバコの摂取に起因しています。大腸がんの早期の発見と治療をもたらす技術の進歩が、世界の大腸がん市場の成長に寄与しています。しかし、大腸がん治療に使用される生物学的製剤に関連する高いコストや、大衆の大腸がんに対する認知の不足は、市場企業にとっての取り組むべき課題となっています。

大腸がんの罹患率の増加

世界の大腸がん市場の主な成長促進要因の1つは、世界中での大腸がんの罹患率の増加です。この増加は、座りがちなライフスタイル、不健康な食生活、汚染レベルの増加、老年人口の増加などのさまざまな要因によるものと考えられます。都会でデスクワークの多い生活を送る人が増えるにつれ、大腸がんの有病率は上昇の一途をたどっており、スクリーニング、診断、治療ソリューションの強化が必要となっています。医療提供者や製薬企業は、増大する健康問題に対処するため、より効果的な診断ツールや治療法を開発する研究開発に多額の投資を行っています。

WHOの発表によれば、結腸がんは世界におけるがん関連死亡原因の第2位です。American Society of Clinical Oncologyが発表したデータによると、2023年に米国で推定15万3,020人の成人が大腸がんと診断されます。この数字には、結腸がん10万6,970例（男性5万4,420例、女性5万2,550例）、直腸がん4万6,050例（男性2万7,440例、女性1万8,610例）が含まれます。大腸がんは世界で3番目に多く診断されるがんです。

がんスクリーニングにおける体外診断技術の進歩

腫瘍学の分野における医療技術の絶え間ない進歩が、世界の大腸がん市場を牽引しています。PCR、In-situハイブリダイゼーション、次世代シーケンシングなどの体外診断法ががん診断に活用および最適化され、より効果的な治療計画や個別化治療のオプションを可能にしています。さらに、免疫組織化学、マイクロアレイ技術、フローサイトメトリーなどの診断法における画期的な進歩は、患者の転帰を著しく改善し、従来の診断技術に伴うエラーを減少させています。

製薬企業が革新的な新治療法を発表していることから、これらの進歩により大腸がん患者の治療の質が向上し、市場の大幅な成長が促進されています。2023年3月、BGI Genomicsは、スロバキアの地域企業Zentyaとの提携でCOLOTECTTM 1.0がスロバキアに導入されることを発表しました。スロバキア初の大腸がんの便中DNA検査が利用できるようになりました。便中DNAは、非侵襲性スクリーニング検査であるCOLOTECTTM 1.0で使用され、大腸がんだけでなく前がん病変も検出します。COLOTECTTM 1.0は、複雑なメチル化特異的PCR（MSP）技術を用いて、患者の糞便サンプルから大腸がんバイオマーカーを検出します。

増加する資金提供と政府の取り組み

政府組織、団体、機関は啓蒙活動を通じて大腸がんのスクリーニングと治療を積極的に推進しており、市場成長を促進しています。研究助成金の増加により、大腸がんの原因究明、新治療法の開発、既存治療法の改良など、より広範な研究が可能になっています。広範な研究開発は、早期発見法やより効果的な治療法のブレークスルーにつながり、ひいては命を救います。

当レポートでは、世界の大腸がん市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界の大腸がん市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界の大腸がん市場の見通し（2017年～2031年）

• 市場規模と予測
  • 金額
  • 数量
• 治療タイプ別
  • 手術
  • 放射線治療
  • 化学療法
  • 標的療法
  • 免疫療法
  • その他の治療
• 診断別
  • 体外診断検査
  • イメージング
  • 生検技術
  • その他
• エンドユーザー別
  • がん研究機関
  • 病院
  • 外来診療センター
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 市場シェア：企業別（2023年）

第6章 世界の大腸がん市場の見通し：地域別（2017年～2031年）

• 北米
  • 市場規模と予測
  • 治療タイプ別
  • 診断別
  • エンドユーザー別
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド
• 南米
  • ブラジル
  • アルゼンチン
• アジア太平洋
  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第7章 市場マッピング（2023年）

• 治療タイプ別
• 診断別
• エンドユーザー別
• 地域別

第8章 マクロ環境と産業構造

• 需給分析
• 輸出入の分析 - 数量と金額
• サプライ/バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第9章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第10章 規制枠組みとイノベーション

• 臨床試験
• 特許情勢
• 規制当局の承認
• イノベーション/新技術

第11章 主要企業情勢

• マーケットリーダー上位5社の競合マトリクス
• マーケットリーダー上位5社の市場収益分析（2023年）
• 合併と買収/合弁事業（該当する場合）
• SWOT分析（市場参入企業5社）
• 特許分析（該当する場合）

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

• Amgen Inc.
• Abbott Laboratories
• Bruker Corporation
• Epigenomics AG
• Clinical Genomics Technologies Pvt. Ltd.
• VolitionRx Limited
• F. Hoffmann-La Roche Ltd
• Sanofi S.A
• Quest Diagnostics Incorporated
• Merck KGaA

第15章 戦略的推奨事項

第16章 当社について、免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 2. Global Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 3. Global Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 4. Global Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 5. Global Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 6. Global Colorectal Cancer Market Share (%), By Region, 2017-2031F
• Figure 7. North America Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 8. North America Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 9. North America Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 10. North America Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 11. North America Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 12. North America Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 13. United States Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 14. United States Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 15. United States Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 16. United States Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 17. United States Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 18. Canada Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 19. Canada Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 20. Canada Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 21. Canada Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 22. Canada Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 23. Mexico Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 24. Mexico Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 25. Mexico Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 26. Mexico Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 27. Mexico Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 28. Europe Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 29. Europe Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 30. Europe Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 31. Europe Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 32. Europe Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 35. Germany Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 36. Germany Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 37. Germany Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 38. Germany Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 39. France Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 40. France Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 41. France Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 42. France Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 43. France Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 44. Italy Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 45. Italy Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 46. Italy Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 47. Italy Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 48. Italy Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 49. United Kingdom Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 50. United Kingdom Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 51. United Kingdom Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 52. United Kingdom Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 53. United Kingdom Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 54. Russia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 55. Russia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 56. Russia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 57. Russia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 58. Russia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 59. Netherlands Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 60. Netherlands Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 61. Netherlands Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 62. Netherlands Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 63. Netherlands Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 64. Spain Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 65. Spain Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 66. Spain Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 67. Spain Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 68. Spain Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 69. Turkey Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 70. Turkey Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 71. Turkey Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 72. Turkey Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 73. Turkey Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 74. Poland Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 75. Poland Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 76. Poland Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 77. Poland Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 78. Poland Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 79. South America Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 80. South America Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 81. South America Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 82. South America Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 83. South America Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 84. South America Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 86. Brazil Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 87. Brazil Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 88. Brazil Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 89. Brazil Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 90. Argentina Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 91. Argentina Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 92. Argentina Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 93. Argentina Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 94. Argentina Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 95. Asia-Pacific Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 97. Asia-Pacific Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 98. Asia-Pacific Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 99. Asia-Pacific Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 100. Asia-Pacific Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 101. India Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 102. India Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 103. India Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 104. India Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 105. India Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 106. China Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 107. China Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 108. China Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 109. China Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 110. China Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 111. Japan Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 112. Japan Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 113. Japan Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 114. Japan Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 115. Japan Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 116. Australia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 117. Australia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 118. Australia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 119. Australia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 120. Australia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 121. Vietnam Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 122. Vietnam Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 123. Vietnam Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 124. Vietnam Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 125. Vietnam Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 126. South Korea Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 127. South Korea Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 128. South Korea Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 129. South Korea Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 130. South Korea Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 131. Indonesia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 132. Indonesia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 133. Indonesia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 134. Indonesia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 135. Indonesia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 136. Philippines Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 137. Philippines Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 138. Philippines Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 139. Philippines Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 140. Philippines Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 141. Middle East & Africa Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 143. Middle East & Africa Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 144. Middle East & Africa Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 145. Middle East & Africa Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 146. Middle East & Africa Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 149. Saudi Arabia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 150. Saudi Arabia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 151. Saudi Arabia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 152. UAE Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 153. UAE Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 154. UAE Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 155. UAE Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 156. UAE Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 157. South Africa Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 158. South Africa Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 159. South Africa Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 160. South Africa Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 161. South Africa Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global colorectal cancer market size was valued at USD 15.06 billion in 2023, and is expected to reach USD 20.72 billion in 2031, with a CAGR of 4.07% for the forecast period between 2024 and 2031F. The market for colorectal cancer therapies and diagnostics has witnessed substantial growth in recent years, driven by a combination of factors such as the increasing prevalence of colorectal cancer, advancements in medical technology, and growing awareness. According to WHO, colorectal cancer is the third most common cancer, covering about 10% of all cancer cases. Increasing research and development in the field of colorectal cancer is driving the market through new and advanced products. Additionally, a strong pipeline of new drugs and government initiatives to eradicate cancer are anticipated to drive the global colorectal cancer market. The surge in the prevalence of colorectal cancer can be attributed to inherited mutations in genes, inflammatory bowel diseases, hormonal and lifestyle changes, and alcohol and tobacco consumption. Technological advancements that result in early detection and treatment of colorectal cancer are contributing to the growth of the global colorectal cancer market. However, the high cost associated with biologics used for colorectal cancer treatment and the lack of awareness about colorectal cancer among the general population is the challenges for market players to tackle.

Increasing Incidence of Colorectal Cancer

One of the primary factors propelling the growth of global colorectal cancer market is the increase in the incidence of colorectal cancer cases across the globe. This rise can be attributed to various factors, including sedentary lifestyles, unhealthy dietary habits, increasing pollution levels, and the growing geriatric population. As more people lead increasingly urban and desk-bound lives, the prevalence of colorectal cancer continues to climb, necessitating enhanced screening, diagnosis, and treatment solutions. Healthcare providers and pharmaceutical companies invest heavily in research and development to develop more effective diagnostic tools and treatments to address growing health concerns.

As per WHO, colon cancer is the second leading cause of cancer-related deaths worldwide. According to data published by American Society of Clinical Oncology, in 2023, an estimated 153,020 adults in the United States will be diagnosed with colorectal cancer. These numbers include 106,970 new cases of colon cancer (54,420 men and 52,550 women) and 46,050 new cases of rectal cancer (27,440 men and 18,610 women). Worldwide, colorectal cancer is the third most diagnosed cancer.

Advancements in In-Vitro Diagnostic Technologies for Cancer Screening

The continuous advancements of medical technology in the field of oncology have been instrumental in driving the global colorectal cancer market. In-vitro diagnostic methods like PCR, In-situ hybridization, and next-generation sequencing are utilized and optimized for cancer diagnostics, allowing for more effective treatment planning and personalized therapy options. Moreover, breakthroughs in diagnostic methods, such as immunohistochemistry, microarray technique, and flow cytometry are significantly improving patient outcomes and reducing the errors associated with conventional diagnostics techniques.

These advancements are enhancing the quality of care for colorectal cancer patients and driving substantial growth in the market as pharmaceutical companies are launching new and innovative treatments. In March 2023, BGI Genomics announced that COLOTECTTM 1.0 would be introduced in Slovakia in collaboration with the regional business Zentya. One of the country's first fecal DNA tests for colorectal cancer has now been made available. Fecal DNA is used by COLOTECTTM 1.0, a non-invasive screening test, to detect precancerous abnormalities as well as colorectal cancer. It uses multiplex methylation-specific PCR (MSP) technology to detect colorectal cancer biomarkers in fecal samples of patients.

Increasing Funding and Government Initiatives

Government organizations, associations, and agencies are actively promoting the screening and treatment of colorectal cancer through awareness initiatives, thereby fostering market growth. Increased research grants have enabled more extensive research into the causes of colorectal cancer, development of new treatments, and improvement of existing therapies. Extensive research and development can lead to breakthroughs in early detection methods and more effective treatment options, ultimately saving lives.

The government is consistently providing research grants each year for development of novel colorectal cancer therapies. In 2021, National Cancer Institute (United States) invested USD 248 million for colorectal cancer research. As per fact sheet published by The White House, American government invested USD 394.5 million during the 2022-2023, in CDC's cancer initiatives that includes Colorectal Cancer Control Program to increase colorectal cancer screening rates among people aged 45 to 75 years.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the colorectal cancer market, affecting various aspects of research, diagnosis, treatment, and patient care. During the pandemic, many non-urgent medical procedures, including colorectal cancer screenings, were postponed, or canceled to prioritize COVID-19 patients and reduce the risk of virus transmission. The delay in screenings led to lower identification of cancer cases at more advanced stages, potentially reducing the chances of successful treatment. Many individuals with colorectal cancer or symptoms that could be an indication of the disease were postponed or avoided due to concerns about COVID-19 transmission in healthcare settings. Conclusively, the COVID-19 pandemic had a multifaceted impact on the colorectal cancer market, affecting screening, diagnosis, treatment, and patient care.

Key Players Landscape and Outlook

The landscape of key players in the colorectal cancer market includes a mix of pharmaceutical companies, medical device manufacturers, and diagnostic service providers. These organizations are actively involved in various aspects of colorectal cancer, including research, drug development, diagnostics, and treatment. The colorectal cancer market is highly dynamic, with ongoing research, drug development, and advancements in diagnostic and treatment modalities. These key players are at the forefront of efforts to combat colorectal cancer and improve patient outcomes.

For instance, Takeda and Hutchmed (China) Limited announced in May 2023 about the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, has been granted priority review by the United States Food and Drug Administration (FDA) for the treatment of adult patients with metastatic colorectal cancer that has already received prior treatment.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Colorectal Cancer Market

4. Executive Summary

5. Global Colorectal Cancer Market Outlook, 2017-2031F

• 5.1 Market Size & Forecast
  • 5.1.1 By Value
  • 5.1.2 By Volume
• 5.2 By Treatment Type
  • 5.2.1 Surgery
  • 5.2.2 Radiation therapy
  • 5.2.3 Chemotherapy
    • 5.2.3.1 Alkylating Agents
    • 5.2.3.2 Antimetabolites
    • 5.2.3.3 Others
  • 5.2.4 Targeted therapy
  • 5.2.5 Immunotherapy
    • 5.2.5.1 Panitumumab
    • 5.2.5.2 Cetuximab
    • 5.2.5.3 Bevacizumab
    • 5.2.5.4 Others
  • 5.2.6 Other Treatments
• 5.3 By Diagnosis
  • 5.3.1 In-vitro Diagnostic Testing
    • 5.3.1.1 Polymerase Chain Reaction (PCR)
    • 5.3.1.2 Blood Test
    • 5.3.1.3 In-situ Hybridization (ISH)
    • 5.3.1.4 Immunohistochemistry
    • 5.3.1.5 Next-generation Sequencing (NGS)
    • 5.3.1.6 Microarrays
    • 5.3.1.7 Flow Cytometry
    • 5.3.1.8 Immunoassays
    • 5.3.1.9 Other In-vitro Diagnostic Testing Technologies
  • 5.3.2 Imaging
    • 5.3.2.1 Magnetic Resonance Imaging (MRI)
    • 5.3.2.2 Computed Tomography (CT)
    • 5.3.2.3 Positron Emission Tomography (PET)
    • 5.3.2.4 Mammography
    • 5.3.2.5 Ultrasound
  • 5.3.3 Biopsy Technologies
  • 5.3.4 Others
• 5.4 By End-user
  • 5.4.1 Cancer Research Institutes
  • 5.4.2 Hospitals
  • 5.4.3 Ambulatory Care Centers
  • 5.4.4 Others
• 5.5 By Region
  • 5.5.1 North America
  • 5.5.2 Europe
  • 5.5.3 Asia Pacific
  • 5.5.4 South America
  • 5.5.5 Middle East & Africa
• 5.6 By Company Market Share (%), 2023

6. Global Colorectal Cancer Market Outlook, By Region, 2017-2031F

• 6.1. North America*
  • 6.1.1. Market Size & Forecast
    • 6.1.1.1. By Value
    • 6.1.1.2. By Volume
  • 6.1.2. By Treatment Type
    • 6.1.2.1. Surgery
    • 6.1.2.2. Radiation therapy
    • 6.1.2.3. Chemotherapy
    • 6.1.2.3.1. Alkylating Agents
    • 6.1.2.3.2. Antimetabolites
    • 6.1.2.3.3. Others
    • 6.1.2.4. Targeted therapy
    • 6.1.2.5. Immunotherapy
    • 6.1.2.5.1. Panitumumab
    • 6.1.2.5.2. Cetuximab
    • 6.1.2.5.3. Bevacizumab
    • 6.1.2.5.4. Others
    • 6.1.2.6. Other Treatments
  • 6.1.3. By Diagnosis
    • 6.1.3.1. In-vitro Diagnostic Testing
    • 6.1.3.1.1. Polymerase Chain Reaction (PCR)
    • 6.1.3.1.2. Blood Test
    • 6.1.3.1.3. In-situ Hybridization (ISH)
    • 6.1.3.1.4. Immunohistochemistry
    • 6.1.3.1.5. Next-generation Sequencing (NGS)
    • 6.1.3.1.6. Microarrays
    • 6.1.3.1.7. Flow Cytometry
    • 6.1.3.1.8. Immunoassays
    • 6.1.3.1.9. Other In-vitro Diagnostic Testing Technologies
    • 6.1.3.2. Imaging
    • 6.1.3.2.1. Magnetic Resonance Imaging (MRI)
    • 6.1.3.2.2. Computed Tomography (CT)
    • 6.1.3.2.3. Positron Emission Tomography (PET)
    • 6.1.3.2.4. Mammography
    • 6.1.3.2.5. Ultrasound
    • 6.1.3.3. Biopsy Technologies
    • 6.1.3.4. Others
  • 6.1.4. By End-user
    • 6.1.4.1. Cancer Research Institutes
    • 6.1.4.2. Hospitals
    • 6.1.4.3. Ambulatory Care Centers
    • 6.1.4.4. Others
  • 6.1.5. United States*
    • 6.1.5.1. Market Size & Forecast
    • 6.1.5.1.1. By Value
    • 6.1.5.1.2. By Volume
    • 6.1.5.2. By Treatment Type
    • 6.1.5.2.1. Surgery
    • 6.1.5.2.2. Radiation therapy
    • 6.1.5.2.3. Chemotherapy
    • 6.1.5.2.3.1. Alkylating Agents
    • 6.1.5.2.3.2. Antimetabolites
    • 6.1.5.2.3.3. Others
    • 6.1.5.2.4. Targeted therapy
    • 6.1.5.2.5. Immunotherapy
    • 6.1.5.2.5.1. Panitumumab
    • 6.1.5.2.5.2. Cetuximab
    • 6.1.5.2.5.3. Bevacizumab
    • 6.1.5.2.5.4. Others
    • 6.1.5.2.6. Other Treatments
    • 6.1.5.3. By Diagnosis
    • 6.1.5.3.1. In-vitro Diagnostic Testing
    • 6.1.5.3.1.1. Polymerase Chain Reaction (PCR)
    • 6.1.5.3.1.2. Blood Test
    • 6.1.5.3.1.3. In-situ Hybridization (ISH)
    • 6.1.5.3.1.4. Immunohistochemistry
    • 6.1.5.3.1.5. Next-generation Sequencing (NGS)
    • 6.1.5.3.1.6. Microarrays
    • 6.1.5.3.1.7. Flow Cytometry
    • 6.1.5.3.1.8. Immunoassays
    • 6.1.5.3.1.9. Other In-vitro Diagnostic Testing Technologies
    • 6.1.5.3.2. Imaging
    • 6.1.5.3.2.1. Magnetic Resonance Imaging (MRI)
    • 6.1.5.3.2.2. Computed Tomography (CT)
    • 6.1.5.3.2.3. Positron Emission Tomography (PET)
    • 6.1.5.3.2.4. Mammography
    • 6.1.5.3.2.5. Ultrasound
    • 6.1.5.3.3. Biopsy Technologies
    • 6.1.5.3.4. Others
    • 6.1.5.4. By End-user
    • 6.1.5.4.1. Hospitals
    • 6.1.5.4.2. Cancer Research Institutes
    • 6.1.5.4.3. Ambulatory Care Centers
    • 6.1.5.4.4. Others
  • 6.1.6. Canada
  • 6.1.7. Mexico

All segments will be provided for all regions and countries covered:

• 6.2. Europe
  • 6.2.1. Germany
  • 6.2.2. France
  • 6.2.3. Italy
  • 6.2.4. United Kingdom
  • 6.2.5. Russia
  • 6.2.6. Netherlands
  • 6.2.7. Spain
  • 6.2.8. Turkey
  • 6.2.9. Poland
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Argentina
• 6.4. Asia-Pacific
  • 6.4.1. India
  • 6.4.2. China
  • 6.4.3. Japan
  • 6.4.4. Australia
  • 6.4.5. Vietnam
  • 6.4.6. South Korea
  • 6.4.7. Indonesia
  • 6.4.8. Philippines
• 6.5. Middle East & Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. South Africa

7. Market Mapping, 2023

• 7.1. By Treatment Type
• 7.2. By Diagnosis
• 7.3. By End-user
• 7.4. By Region

8. Macro Environment and Industry Structure

• 8.1. Supply Demand Analysis
• 8.2. Import Export Analysis - Volume and Value
• 8.3. Supply/Value Chain Analysis
• 8.4. PESTEL Analysis
  • 8.4.1. Political Factors
  • 8.4.2. Economic System
  • 8.4.3. Social Implications
  • 8.4.4. Technological Advancements
  • 8.4.5. Environmental Impacts
  • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 8.5. Porter's Five Forces Analysis
  • 8.5.1. Supplier Power
  • 8.5.2. Buyer Power
  • 8.5.3. Substitution Threat
  • 8.5.4. Threat from New Entrant
  • 8.5.5. Competitive Rivalry

9. Market Dynamics

• 9.1. Growth Drivers
• 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

• 10.1. Clinical Trials
• 10.2. Patent Landscape
• 10.3. Regulatory Approvals
• 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)
• 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

• 14.1. Amgen Inc.
  • 14.1.1. Company Details
  • 14.1.2. Key Management Personnel
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As reported)
  • 14.1.5. Key Market Focus & Geographical Presence
  • 14.1.6. Recent Developments
• 14.2. Abbott Laboratories
• 14.3. Bruker Corporation
• 14.4. Epigenomics AG
• 14.5. Clinical Genomics Technologies Pvt. Ltd.
• 14.6. VolitionRx Limited
• 14.7. F. Hoffmann-La Roche Ltd
• 14.8. Sanofi S.A
• 14.9. Quest Diagnostics Incorporated
• 14.10. Merck KGaA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer